William Robinson, MD
Rheumatology · Stanford, CANPI 1417975491
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,805 of the $7,465 with a category attached, or 91.2%. E.r. Squibb & Sons, L.L.C. accounts for 79.0% of it on its own, with 4 other manufacturers making up the rest.
Across 16 payments — averaging $466.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$6K
- Kiniksa Pharmaceuticals International, PLC$1K
- Merck$111
- Janssen Research & Development, LLC$97
- Gilead$59
Across 21 payments — averaging $243,207 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$4.1M
- Gilead$587K
- Sanofi US Services Inc.$394K
- Bio-rad Laboratories, Inc.$80
What the payments were for
- Consulting fees$6,80591%
- Travel & lodging$2123%
- Food & beverage$4486%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $5,894 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $1,305 |
| Merck | 2 | $111 |
| Janssen Research & Development, LLC | 1 | $97 |
| Gilead | 3 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENCIA$5,689
How this compares
$7,465 in reported general payments places this provider in the 65th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Stanford
- Mark GenoveseStanford$404K
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.